Table S2.
Effect of induction regimens for transplant-eligible patients with NDMM on OS
| VTDC | 2.2 (0.69–6.9) |
1.6 (0.61–4.2) |
1.7 (0.64–4.3) |
2.0 (0.85–4.9) |
1.4 (0.64–3.0) |
2.1 (0.85–5.3) |
1.3 (0.59–2.7) |
2.0 (0.72–5.6) |
1.2 (0.58–2.3) |
|---|---|---|---|---|---|---|---|---|---|
| 0.46 (0.15–1.4) |
Cy-Dex | 0.73 (0.23–2.3) |
0.75 (0.36–1.6) |
0.93 (0.45–1.9) |
0.63 (0.24–1.6) |
0.97 (0.49–1.9) |
0.58 (0.22–1.5) |
0.91 (0.40–2.1) |
0.52 (0.21–1.3) |
| 0.63 (0.24–1.6) |
1.4 (0.44–4.3) |
Dex | 1.0 (0.40–2.6) |
1.3 (0.54–3.0) |
0.86 (0.48–1.5) |
1.3 (0.54–3.3) |
0.79 (0.39–1.6) |
1.3 (0.46–3.4) |
0.72 (0.37–1.4) |
| 0.60 (0.24–1.6) |
1.3 (0.64–2.8) |
0.97 (0.38–2.5) |
PAD | 1.2 (0.86–1.8) |
0.84 (0.40–1.7) |
1.3 (1.0–1.7) |
0.77 (0.37–1.6) |
1.2 (0.72–2.0) |
0.70 (0.36–1.3) |
| 0.49 (0.20–1.2) |
1.1 (0.51–2.2) |
0.78 (0.33–1.8) |
0.81 (0.56–1.2) |
TAD | 0.67 (0.36–1.3) |
1.0 (0.81–1.3) |
0.62 (0.33–1.2) |
0.98 (0.58–1.6) |
0.56 (0.33–0.96) |
| 0.72 (0.34–1.6) |
1.6 (0.61–4.2) |
1.2 (0.65–2.1) |
1.2 (0.58–2.5) |
1.5 (0.79–2.8) |
TD | 1.5 (0.78–3.1) |
0.91 (0.63–1.3) |
1.5 (0.64–3.3) |
0.83 (0.60–1.2) |
| 0.47 (0.19–1.2) |
1.0 (0.52–2.0) |
0.75 (0.30–1.8) |
0.77 (0.60–1.0) |
0.96 (0.74–1.2) |
0.65 (0.33–1.3) |
VAD | 0.59 (0.30–1.2) |
0.94 (0.60–1.5) |
0.54 (0.30–0.98) |
| 0.79 (0.37–1.7) |
1.7 (0.66–4.6) |
1.3 (0.63–2.5) |
1.3 (0.63–2.7) |
1.6 (0.86–3.1) |
1.1 (0.75–1.6) |
1.7 (0.85–3.4) |
VBMCP-VBAD-B | 1.6 (0.70–3.6) |
0.91 (0.65–1.3) |
| 0.50 (0.18–1.4) |
1.1 (0.48–2.5) |
0.80 (0.29–2.2) |
0.82 (0.49–1.4) |
1.0 (0.61–1.7) |
0.69 (0.30–1.6) |
1.1 (0.68–1.7) |
0.63 (0.28–1.4) |
VD | 0.57 (0.27–1.2) |
| 0.87 (0.44–1.7) |
1.9 (0.77–4.7) |
1.4 (0.71–2.7) |
1.4 (0.75–2.8) |
1.8 (1.0–3.1) |
1.2 (0.86–1.7) |
1.9 (1.0–3.4) |
1.1 (0.79–1.5) |
1.7 (0.82–3.7) |
VTD |
Note: Data presented as HR (95% CI).
Abbreviations: Cy-Dex, cyclophosphamide plus dexamethasone; Dex, dexamethasone; NDMM, newly diagnosed multiple myeloma; OS, overall survival; PAD, bortezomib plus doxorubicin plus dexamethasone; TAD, thalidomide plus doxorubicin plus dexamethasone; TD, thalidomide plus dexamethasone; VAD, vincristine plus doxorubicin plus dexamethasone; VBMCP-VBAD-B, BCNU plus vincristine plus melphalan plus prednisone plus dexamethasone plus bortezomib; VTD, bortezomib plus thalidomide plus dexamethasone; VD, bortezomib plus dexamethasone; VTD, bortezomib plus thalidomide plus dexamethasone; VTDC, bortezomib plus thalidomide plus dexamethasone plus cyclophosphamide.